Designer Cytotoxic T cells: Transcription Factor-Based Engineering with FOSL1
Method to enhance persistence and cytotoxicity of T-Cell adoptive therapies.
This technology leverages a transcription factor, FOSL1, overexpressed to enhance T-cell function, boosting tumour-killing efficiency and engagement. It presents a promising advancement for adoptive therapies like CAR-T, TCR-T, and TIL, with broad applications in cancer treatment.
Applications: Immunotherapy, Adoptive Cell Therapy (e.g. CAR-T, TCR-T, TILs)
| Features | Benefits |
|---|---|
| Enhanced cytotoxicity | Destroy tumour cells faster and more effectively, enabling better cancer clearance. |
| Increased T-cell engagement | Improved cytokine production and expression of tissue homing receptors |
| Safety profile | FOSL1 overexpression does not result in non-specific activation – cytotoxicity is triggered only upon tumour engagement |
| Versatility and scalability | Can integrate with existing T-cell therapies (e.g., CAR-T, TCR-T, TIL) |
Awaiting patent and Available For
- Co-development
- Consulting
- Licensing